Thursday, November 26, 2015 Last update: 6:33 AM - Covering Large & Obscure Tech Companies Since 1996

Iris BioTechnologies CEO Simon Chin Will Discuss Big Data at the World's Largest Gathering for Laboratory Medicine at AACC 2014

Companies mentioned in this article: Iris BioTechnologies Inc.

SANTA CLARA, CA--(Marketwired - July 09, 2014) - Iris BioTechnologies Inc. (OTCQB: IRSB) is a life sciences company and is a leader in the Invitro Diagnostic (IVD) industry.

The world's largest annual gathering for laboratory medicine will take place this year at the American Association for Clinical Chemistry (AACC) Conference at the McCormick Convention Center in Chicago on July 27-31. Following the Iris presentation at BIO 2014, the world's largest biotech conference and exhibition, AACC and Diagnostic Marketing Association (DxDMA) jointly invited Simon Chin, President, CEO, and Founder of Iris BioTechnologies to be a panel member to discuss why Big Data is important for the Invitro Diagnostic (IVD) industry.

With Iris having been issued US patent 8,693,751, Artificial Intelligence System for Genetic analysis, in April of this year, Mr. Chin is in a unique position to add expertise to the panel. Iris BioTechnologies' BioWindows™ Big Data Analytics System enables and accelerates the practice of personalized precision medicine.

According to AACC and DxDMA, this year's seminar "will consist of a panel drawn from the healthcare professionals and diagnostic industry leaders who have a vision for how this innovation evolution might look and insight into what laboratorians and IVD manufacturers may expect. Since the laboratory produces an overwhelming amount of data that challenges today's legacy architecture, the future which will include extensive data arrays drawn from next generation sequencing and companion diagnostics, call for contemporary tools and systems to deliver the promise of tomorrow's world."

Organizers of the Seminar believe that diagnostic manufactures should be evaluating the opportunities associated with developing IP protected algorithms that link traditional laboratory and Big Data information to help physicians make difficult diagnostic or therapeutic decisions.

Chin said, "I am looking forward to sharing with the world what Iris has been doing to advance personalized precision medicine through Big Data Analytics. I will also be discussing the overview of some of the state-of-the-art practices required to accelerate the transformation of the Invitro Diagnostic (IVD) industry."

The panel will discuss the integration of data for computational and clinical outcomes and will be moderated by Bob McGonnagle, the Publisher of the College of American Pathologists trade journal, CAPToday.

According to AACC, "The 2014 AACC Annual Meeting is an opportunity for connecting with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine." This meeting also offers the chance to learn about cutting edge technology. The AACC annual meeting has more than 200 new product introductions each year. In addition, it is a place to hear vital research and learn about important changes in the field.

About Iris BioTechnologies Inc.

Iris BioTechnologies Inc. (OTCQB: IRSB) is a life sciences company focused on providing accurate, affordable precision healthcare, which is the future of medicine. Iris offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. In the treatment of cancer, we can achieve precision analysis of chemotherapy effectiveness as well as risk of recurrence. We accomplish this by incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. By analyzing the totality of who a patient is Iris can offer physicians the necessary information to assist their patients in determining the best medical treatment regimen before the treatment even begins. Iris enables personal precision healthcare by matching patient to targeted treatments, and in some cases, including therapies in clinical trials.

The Iris Nano-Biochip™ product pipeline includes: CancerChip™, PrenatalChip™, NeuroChip™ (Alzheimer's and Parkinson diseases), MetabolicChip™ (Diabetes), CardioChip™, and Chips for veterinary, agricultural (e.g., biofuel development), environmental, and other applications. The Iris BioWindows™ artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.

For more information on Iris BioTechnologies Inc., please visit us on the Iris corporate website (, Facebook (, and Twitter (


Iris BioTechnologies Inc.
Simon Chin
President, CEO, and Founder